Experimental combo for tough leukemia shows promise but study halted early
NCT ID NCT03150004
First seen Apr 10, 2026 · Last updated May 06, 2026 · Updated 3 times
Summary
This study tested a chemotherapy combination containing cladribine for people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) had returned or not responded to prior treatment. The goal was to see if the treatment could wipe out signs of the disease in the bone marrow. The study was stopped early, but data from 53 participants was collected to measure remission rates and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.